… big ticket categories. Gross profit increased 2.8% to $ … uncertainty, the Company is providing second quarter 2025 guidance: net sales … , a leading online pet pharmacy, in its family of … capital, financial guidance for second quarter 2025 and fiscal 2025, …

… completed within the second quarter, pending the signing … infrastructure with Woosung Pharmaceutical’s commercial operations. … significantly improve its revenue, helping it meet … second quarter.” The company will provide full support for Woosung Pharmaceutical …

By the numbers   Q1 revenue: $5.74 billion Roughly 1% decrease year over year   Q1 net earnings: $954 million 12% decrease year over year Danaher has joined the chorus of companies predicting hundreds of millions of tariff costs in 2025. Yet, the company, …

By the numbers   Q1 sales: $1.41 billion 6.2% increase year over year   TAVR sales: $1.05 billion 3.8% increase year over year   TMTT sales: $115 million 58.1% increase year over year Edwards Lifesciences maintained full-year financial forecasts on …

… Credit: miniseries Corporate revenues in India are expected … Crisil Intelligence. Operating profit in the quarter is … revenue resulting from significant tariff hikes implemented in the second quarter … pick-ups. The pharmaceutical sector revenue likely grew 8 …

… and services for pharmacies in France are … businesses posted reported revenues down 31.1% … Appendix Breakdown of revenue by quarter and … euros   Q1 Q2 Q3 Q4 Total Software …

… Tariff fear: US probes pharma, semiconductor industries   Product … of total HBM3E revenues in the second quarter,” the company said … with demand feasibility and profitability to enhance investment efficiency … in efforts to continue profit growth with industry- …

… revenue resulting from significant tariff hikes implemented in the second quarter … construction-linked sectors, revenue growth is seen limited … noted. On the profitability front, its associate director … ones such as pharmaceuticals, investment-linked ones …

SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited …

… dividend for the second quarter of 2025 of … profits through small and mid-cap biotechnology companies to leading global pharmaceutical … companies. Royalty Pharma has assembled … leading therapies. Royalty Pharma funds innovation in …